US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Perpetuals.com Ltd

3.46

+0.01000.29%

Post-market: 3.460.00000.00%19:35 EDT

Volume:10K

Turnover:32.49K

Market Cap:28.07M

PE:-0.69

High:3.50

Open:3.44

Low:3.25

Close:3.45

52wk High:8.83

52wk Low:2.42

Shares:8.11M

Float Shares:5.45M

Volume Ratio:0.28

T/O Rate:0.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.9964

EPS(LYR):-0.7902

ROE:-72.52%

ROA:-8.93%

PB:1.17

PE(LYR):-4.38

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Perpetuals.com UpsideOnly Registered User Base Reaches 600,000 in 38 Days

Press Release: Avacta Group Plc: Interim Results for the Six Months to June 30, 2026, and Business Update

Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer

Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/PDC"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PDC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PDC\",,,,,undefined,":{"symbol":"PDC","market":"US","secType":"STK","nameCN":"Perpetuals.com Ltd","latestPrice":3.46,"timestamp":1790971200000,"preClose":3.45,"halted":0,"volume":9573,"hourTrading":{"tag":"盘后","latestPrice":3.46,"preClose":3.46,"latestTime":"19:35 EDT","volume":126,"amount":438.2255,"timestamp":1790984142291,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.002898550724637619,"floatShares":5452700,"shares":8114100,"eps":-4.996365,"marketStatus":"Market Closed","change":0.01,"latestTime":"10-02 16:00:00 EDT","open":3.44,"high":3.498,"low":3.25,"amount":32494.366234499998,"amplitude":0.071884,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.996365,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":5,"listingDate":1690257600000,"exchange":"NASDAQ","adjPreClose":3.45,"postHourTrading":{"tag":"盘后","latestPrice":3.46,"preClose":3.46,"latestTime":"19:35 EDT","volume":126,"amount":438.2255,"timestamp":1790984142291,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.2781593998953804},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PDC\",,,,,undefined,":{"symbol":"PDC","floatShares":5452700,"roa":"-8.93%","roe":"-72.52%","lyrEps":-0.790182,"volumeRatio":0.2781593998953804,"shares":8114100,"dividePrice":0,"high":3.498,"amplitude":0.071884,"preClose":3.45,"low":3.25,"week52Low":2.42,"pbRate":"1.17","psRate":"17.29","week52High":8.83,"institutionHeld":0,"latestPrice":3.46,"eps":-4.996365,"divideRate":0,"volume":9573,"delay":0,"ttmEps":-4.996365,"open":3.44,"prevYearClose":6.475,"prevWeekClose":3.28,"prevMonthClose":3.34,"prevQuarterClose":3.34,"fiveDayClose":3.28,"twentyDayClose":2.71,"sixtyDayClose":4.81},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PDC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-16","symbol":"PDC","defaultRemindTime":1715866200000,"type":"split","dateTimestamp":1715832000000,"forFactor":5,"toFactor":1,"ratio":5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PDC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PDC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PDC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PDC","date":"2026-10-02","current":-0.692503,"percent":0.965517,"low":-20.799035,"twenty":-13.684675,"median":-9.492422,"eighty":-7.615276,"high":-1.484564,"avg":-10.052101,"sd":3.44712,"marketCap":27993776},"quantilePoints":[{"date":"2026-01-23","current":-12.841505,"twenty":-12.726719,"median":-12.554539,"eighty":-12.382359,"marketCap":20820140},{"date":"2026-01-30","current":-9.396756,"twenty":-12.329049,"median":-11.675543,"eighty":-10.201718,"marketCap":15771446},{"date":"2026-02-06","current":-7.275042,"twenty":-12.149167,"median":-9.714799,"eighty":-8.086801,"marketCap":11897223},{"date":"2026-02-13","current":-8.985188,"twenty":-11.515878,"median":-8.985188,"eighty":-7.549471,"marketCap":15130827},{"date":"2026-02-20","current":-8.855994,"twenty":-10.87722,"median":-8.985188,"eighty":-7.579088,"marketCap":14673241},{"date":"2026-02-27","current":-8.742983,"twenty":-10.032842,"median":-8.830662,"eighty":-7.735212,"marketCap":14368184},{"date":"2026-03-06","current":-9.337263,"twenty":-10.032842,"median":-8.985188,"eighty":-8.021273,"marketCap":15191838},{"date":"2026-03-13","current":-9.688387,"twenty":-9.991079,"median":-9.288813,"eighty":-8.290652,"marketCap":15618918},{"date":"2026-03-20","current":-9.233278,"twenty":-9.991079,"median":-9.314811,"eighty":-8.348912,"marketCap":14993551},{"date":"2026-03-27","current":-9.069316,"twenty":-9.96573,"median":-9.348389,"eighty":-8.474222,"marketCap":14581724},{"date":"2026-04-02","current":-9.313761,"twenty":-9.884139,"median":-9.348389,"eighty":-8.689231,"marketCap":15008804},{"date":"2026-04-10","current":-9.533008,"twenty":-9.74834,"median":-9.359515,"eighty":-8.70742,"marketCap":15374872},{"date":"2026-04-17","current":-12.673274,"twenty":-9.884139,"median":-9.362202,"eighty":-8.546978,"marketCap":20438819},{"date":"2026-04-24","current":-13.088049,"twenty":-10.217704,"median":-9.396756,"eighty":-8.70742,"marketCap":21079438},{"date":"2026-05-01","current":-15.050104,"twenty":-11.793949,"median":-9.471088,"eighty":-8.745021,"marketCap":24648605},{"date":"2026-05-08","current":-14.948137,"twenty":-12.890814,"median":-9.496239,"eighty":-8.793369,"marketCap":24526582},{"date":"2026-05-15","current":-13.305836,"twenty":-13.354923,"median":-9.542177,"eighty":-8.845861,"marketCap":21598035},{"date":"2026-05-22","current":-11.365513,"twenty":-13.169042,"median":-9.675854,"eighty":-8.876909,"marketCap":21140450},{"date":"2026-05-29","current":-14.128136,"twenty":-13.74972,"median":-9.719101,"eighty":-8.895541,"marketCap":26275960},{"date":"2026-06-05","current":-12.076178,"twenty":-13.8801,"median":-9.813125,"eighty":-8.952904,"marketCap":22349404},{"date":"2026-06-12","current":-14.872027,"twenty":-13.8801,"median":-9.991079,"eighty":-9.00144,"marketCap":27440229},{"date":"2026-06-18","current":-14.520969,"twenty":-14.245743,"median":-10.18842,"eighty":-9.035091,"marketCap":26709707},{"date":"2026-06-26","current":-11.614912,"twenty":-14.356284,"median":-10.79484,"eighty":-9.128052,"marketCap":21276450},{"date":"2026-07-02","current":-13.769243,"twenty":-14.446364,"median":-10.952611,"eighty":-9.21958,"marketCap":25339979},{"date":"2026-07-10","current":-12.205639,"twenty":-14.446364,"median":-11.365513,"eighty":-9.239186,"marketCap":32585522},{"date":"2026-07-17","current":-8.962642,"twenty":-14.389601,"median":-10.952611,"eighty":-9.21958,"marketCap":23914115},{"date":"2026-07-24","current":-9.476284,"twenty":-14.254526,"median":-10.71246,"eighty":-9.09917,"marketCap":25065786},{"date":"2026-07-31","current":-9.145848,"twenty":-14.247303,"median":-10.285858,"eighty":-9.069924,"marketCap":24862550},{"date":"2026-08-07","current":-7.600862,"twenty":-14.243402,"median":-10.102078,"eighty":-8.962642,"marketCap":20797828},{"date":"2026-08-14","current":-7.895877,"twenty":-14.128136,"median":-9.96573,"eighty":-8.855994,"marketCap":21475282},{"date":"2026-08-21","current":-7.890223,"twenty":-13.901725,"median":-9.813125,"eighty":-8.565167,"marketCap":21543027},{"date":"2026-08-28","current":-7.54419,"twenty":-13.86583,"median":-9.719101,"eighty":-8.219559,"marketCap":20526847},{"date":"2026-09-04","current":-6.589647,"twenty":-13.865684,"median":-9.68212,"eighty":-8.074037,"marketCap":18358995},{"date":"2026-09-11","current":-7.149765,"twenty":-13.859725,"median":-9.551961,"eighty":-7.894746,"marketCap":20120374},{"date":"2026-09-18","current":-7.670838,"twenty":-13.787041,"median":-9.54288,"eighty":-7.752526,"marketCap":21340182},{"date":"2026-09-25","current":-1.685972,"twenty":-13.740832,"median":-9.505721,"eighty":-7.700224,"marketCap":29210896},{"date":"2026-10-02","current":-1.607699,"twenty":-13.684675,"median":-9.492422,"eighty":-7.615276,"marketCap":27993776}],"updateTime":1791077513725},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PDC\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672754421","title":"Perpetuals.com UpsideOnly Registered User Base Reaches 600,000 in 38 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754421?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:00","pubTimestamp":1790856058,"startTime":"0","endTime":"0","summary":"Perpetuals.com UpsideOnly registered user base reaches 600,000 in 38 daysPerpetuals.com’s UpsideOnly paper-trading platform topped 600,000 registered users on Sept. 26, doubling from 300,000.Added abo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDLc1qfyS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4123","PDC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671320189","title":"Press Release: Avacta Group Plc: Interim Results for the Six Months to June 30, 2026, and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2671320189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671320189?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:00","pubTimestamp":1790769600,"startTime":"0","endTime":"0","summary":"LONDON and PHILADELPHIA, Sept. 30, 2026  -- Avacta Therapeutics , a life sciences company developing innovative, targeted oncology drugs, today publishes its unaudited interim results for the six months ended June 30, 2026 .H1 highlights and post periodResearch & developmentNext Generation pre|CISION pipeline-- AVA6103 . -- Preliminary preclinical and clinical data with AVA6103 have been. presented recently. Data reported in the Phase 1a trial in. patients with select solid tumors demonstrate proof of mechanism. demonstrates a clean safety profile through the first three. dose levels, including a payload dose level 50% higher than. -- The comparison of the preclinical modeled pharmacokinetic.  data and clinical trial PK data demonstrates an. exceptional alignment through the first 3 dose levels with. controlled release of exatecan evident in patients for days. -- The first head-to-head preclinical comparison of AVA6103 and. Enhertu, a marketed antibody drug conjugate  that targets. HER","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","R","PK","IE00B5TLWC47.USD","IE00BFXG0V08.USD","BK4121","BK4588","BK4080","BK4232","BK4231","LU1093756168.USD","BK4218","LU2413666426.HKD","BK4567","ADC","LU2413666699.HKD","BK4139","BK4022","IE00BYQQ9H92.USD","LU1721428933.USD","BK4533","IND","KBWY","NETL","BK4181","LU0347712357.USD","LU2211817866.USD","BK4585","LU1093756325.SGD","MTD","PDC","AVCTF","BK4123"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670482204","title":"Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2670482204","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670482204?lang=en_us&edition=fundamental","pubTime":"2026-09-25 14:00","pubTimestamp":1790316000,"startTime":"0","endTime":"0","summary":"LONDON and PHILADELPHIA, Sept.  25, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, the \"Company\", \"Avacta\"), a life sciences company developing innovative, targeted oncology drugs, today ann","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/25/3368853/0/en/avacta-group-plc-the-focus-01-clinical-trial-design-and-preclinical-data-further-demonstrate-the-potential-of-ava6103-at-aacr-conference-on-pancreatic-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4571","BK4552","BK4080","IE00B5TLWC47.USD","PDC","BK4565","BK4509","BK4563","LU0456842615.SGD","LU0828238088.HKD","KBWY","IE00BYQNZ168.SGD","NETL","LU0359202008.SGD","BK4218","MTD","IE00BYQQ9H92.USD","IE00BYTNYN87.SGD","BK4231","BK4533","BK4567","BK4585","ADC","LU0269904917.USD","LU0509642566.USD","PDX","SG9999011746.SGD","BK4121","BK4535","BK4526","LU1023057109.AUD","LU2413666699.HKD","LU0359201612.USD","LU2413666426.HKD","TME","LU2211817866.USD","IE00BFXG0V08.USD","01698","BK4123","LU1721428933.USD","BK4588","BK4181","LU1093756168.USD","BK4548","LU0347712357.USD","BK4531","LU2039709279.SGD","PK","BK4108","IE00B12V2V27.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667984870","title":"Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667984870","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667984870?lang=en_us&edition=fundamental","pubTime":"2026-09-16 23:00","pubTimestamp":1789570800,"startTime":"0","endTime":"0","summary":"LONDON and PHILADELPHIA, Sept.  16, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces today that it has achiev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/16/3363359/0/en/avacta-achieves-clinical-proof-of-mechanism-for-the-next-generation-of-pre-cision-medicines-with-ava6103-fap-exd-in-the-phase-1-focus-01-trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0347712357.USD","LU1169590202.USD","LU1093756168.USD","LU2413666426.HKD","BK4181","LU1093756325.SGD","BK4567","IE00BYQQ9H92.USD","KBWY","BK4080","BK4585","PD","PDC","NETL","BK4533","BK4588","BK4023","PK","BK4218","BK4123","ADC","LU1169589451.USD","BK4121","LU2413666699.HKD","LU2211817866.USD","BK4548","IE00BFXG0V08.USD","MDCO","BK4231","LU1721428933.USD","IE00B5TLWC47.USD","MTD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":17,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PDC\",params:#limit:6,delay:false,,,undefined,":[]}}